5 YEAR RESULTS OF EJECTION FRACTION IN PATIENTS WITH ACUTE CORONARY SYNDROME AFER MULTIVESSEL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY
https://doi.org/10.38109/2225-1685-2019-2-46-53
Abstract
Aim. The aim of this randomized clinic trial was to study 5-year follow up of morbidity and mortality in patients with acute coronary syndrome after conducted multivessel percutaneous transluminal coronary angioplasty (PTCA).
Material and methods. The trial was carried out in two groups with EF 35% for assessment of acute coronary syndrome impact to myocardial revascularization. 742 patients were included to the trial. All patients were undergone coronary angiography admitted during 6 hours after MI and followed through PTCA. 5 year follow-up of morbidity was investigated on these patients considering an initial EF.
Results. 129 patients had got EF indices lower than 35%. Only 122 patients (94%) among these ones completed the 5 year follow up. 613 patients had got EF with initial indices higher than 35%. Average age of patients with EF 35% - 55,8 year (SD 10-17). 110 patients (90,2%) with EF 35% were men. 12 (9,8%) women were in the group with EF35%. Only 577 (93,8%) of them completed the follow up. The estimation of morbidity and mortality were done in divided groups by EF for both sex. Also there were investigated and compared the causes of death in both groups.
Conclusion. EF was determined as an important factor influenced morbidity and mortality in patients after PTCA.
About the Author
F. N. Ibrahimov
Azerbaijan Medical University
Azerbaijan
Azerbaijan
Department of Anaesthesiology and Resuscitation, Associate Professor
+99450 209 19 56
Fatali Khan Khoyski St., 101a, Baku, Narimanov, AZ 1072
References
1. Cowburn G, Bhatnagar P, Løgstrup S. Cardiovascular disease prevention in Europe- the unfinished agenda. EuroHeart work package 5: National plans, policies and measures impacting in cardiovascular health promotion and cardiovascular disease prevention. European Heart Network; 2009.
2. Rosamond WD, Chambless LE, Heiss G, Mosley TH, Coresh J, Whitsel E, et al. Twenty-two-year trends in incidence of myocardial infarction, coronary heart disease mortality, and case fatality in 4 US communities, 1987–2008. Circulation. 2012; 125: 1848-1857. doi: 10.1161/CIRCULATIONAHA.111.047480
3. Journath G, Hammar N, Elofsson S, Linnersjö A, Vikström M, Walldius G, et al. Time Trends in Incidence and Mortality of Acute Myocardial Infarction, and All-Cause Mortality following a Cardiovascular Prevention Program in Sweden. PLoS One. 2015, 10 (11): e0140201 doi: 10.1371/journal.pone.0140201
4. 5. Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med. 2010; 362 (23): 2155-2165. doi: 10.1056/NEJMoa0908610
5. Montalescot G1, Dallongeville J, Van Belle E, Rouanet S, Baulac C, Degrandsart A, et al.; OPERA Investigators. STEMI and NSTEMI: are they so different? 1-year outcomes in acute myocardial infarction as defined by the ESC/ACC definition (the OPERA registry). Eur Heart J., 2007; 28 (12): 1409-1417. doi: 10.1093/eurheartj/ehm031
6. Wijeysundera HC, Machado M, Farahati F, Wang X, Witteman W, van der Velde G, et al. Association of temporal trends in risk factors and treatment uptake with coronary heart disease mortality, 1994–2005. JAMA, 2010; 303 (18): 1841-1847. doi: 10.1001/jama.2010.580
7. Morice MC, Serruys PW, Sousa JE, et al. RAVEL Study Group A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med. 2002; 346 (23): 1773-1780.
8. Price MJ, Angiolillo DJ. Platelet inhibitor agents. In: Topol EJ, Teirstein PS, editors. Textbook of Interventional Cardiology. 7th. Philadelphia, PA: Elsevier; 2016: 151-204.
9. Eng MH, Moses JW, Teirstein PS. Complications of percutaneous coronary intervention. In: Topol EJ, Teirstein PS, editors. Textbook of Interventional Cardiology. 7th. Philadelphia, PA: Elsevier; 2016: 464-481.
10. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361(9351): 13-20.
11. Bavry AA, Kumbhani DJ, Rassi AN, Bhatt DL, Askari AT. Benefit of early invasive therapy in acute coronary syndromes: a metaanalysis of contemporary randomized clinical trials. J Am Coll Cardiol. 2006;48(7):1319-1325.
12. Noa P Yee, Andrea M Siu, James Davis, and John Kao. Recovery of Left Ventricular Function after Percutaneous Coronary Intervention Compared to Coronary Artery Bypass Grafting in Patients with Multi-Vessel Coronary Disease and Left Ventricular Dysfunction. Hawaii J Med Public Health. 2016 Sep; 75(9): 273-277.
13. Gabriel C.Brooks, Byron K.Lee, MASa RajniRao, FengLin, Steven L.Zweibel, Alfred E.Buxton, Mark J.Pletcher, EricVittinghoff, Jeffrey E.Olgin. Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study. Journal of the American College of Cardiology. Volume 67, Issue 10, 15 March 2016: 1186-1196.
14. Yan TD, Padang R, Poh C, et al. Drug-eluting stents versus coronary artery bypass grafting for the treatment of coronary artery disease: a meta-analysis of randomized and nonrandomized studies. J Thorac Cardiovasc Surg 2011; 141: 1134–44.
Review
For citations:
Ibrahimov F.N. 5 YEAR RESULTS OF EJECTION FRACTION IN PATIENTS WITH ACUTE CORONARY SYNDROME AFER MULTIVESSEL PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY. Eurasian heart journal. 2019;(2):46-53. https://doi.org/10.38109/2225-1685-2019-2-46-53
Views:
384
Email this article 
